Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Bristol Myers表示來自3期DAYBREAK試驗的最新數據顯示，在使用Zeposia（Ozanimod）治療複發性多發性硬化症患者的開放標籤延長期間，腦容積流失率下降的情況得到了持續改善。
Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Bristol Myers表示來自3期DAYBREAK試驗的最新數據顯示，在使用Zeposia（Ozanimod）治療複發性多發性硬化症患者的開放標籤延長期間，腦容積流失率下降的情況得到了持續改善。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間